Odulimomab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOdulimomab

Drug Alias NameAnti-CD11a monoclonal antibody 25.3奥度莫单抗afolimomab25.3 monoclonal antibodyAnti-LFA-1 monoclonal antibody +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionLeukocyte adhesion glycoprotein LFA-1 alpha antagonists

TargetsLeukocyte adhesion glycoprotein LFA-1 alpha

Therapy Area/IndicationsRejection of renal transplantationGraft vs Host Disease

Global Approved IndicationsRejection of renal transplantationGraft vs Host Disease

Approved Indications in ChinaN/A

Original Approved Country/TerritoryFrance

Original Approved Date1997/01/01

Country/TerritoryFrance

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesImmunotech SAS

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsRejection of renal transplantationGraft vs Host Disease

Inactive IndicationsN/A

Other Information

ATC CodeL01XC